Benzinga · Feb 26, 2026
AL
NASDAQ · ALMS
Alumis Inc. Common Stock
Healthcare · Biotechnology
$8.40
Down-$0.50 (-5.89%)
Updated Sep 16, 2026, 4:43 PM
SID Score
3.2/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 3.1B
- P/E ratio
- -12.61
- Dividend yield
- 0.00%
- 52-week range
- $8.31 – $31.35
- Volume
- 4M
- Avg. volume
- 2.96M
Price performance
ALMS price history
1M range · 0 trading sessions · Daily adjusted prices
ALMS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ALMS news
The latest Smart Investors Daily articles mentioning ALMS.
Stock researchCompany · Overview
ALMS research
Overview
Company profile and research snapshot.
Company profile
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | Guggenheim | Neutral | — |
| Sep 2, 2026 | Wells Fargo | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 2, 2026 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Alumis shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $44 price target.
Benzinga · Feb 25, 2026
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Benzinga · Feb 25, 2026
Stifel Initiates Coverage On Alumis with Buy Rating, Announces Price Target of $44
Stifel analyst Alex Thompson initiates coverage on Alumis (NASDAQ:ALMS) with a Buy rating and announces Price Target of $44.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
